{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:33:42Z","timestamp":1770813222179,"version":"3.50.1"},"reference-count":258,"publisher":"Elsevier","isbn-type":[{"value":"9780443235481","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.ircmb.2024.01.005","type":"book-chapter","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T01:11:54Z","timestamp":1708391514000},"page":"167-222","source":"Crossref","is-referenced-by-count":2,"title":["Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2024.01.005_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/cimm.1997.1224","article-title":"Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations","volume":"182","author":"Abrams","year":"1997","journal-title":"Cellular Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrm3255","article-title":"Regulating the regulator: Post-translational modification of RAS","volume":"13","author":"Ahearn","year":"2011","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","article-title":"SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors","volume":"26","author":"Ahmed","year":"2019","journal-title":"Cell Reports"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib4","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H","article-title":"Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung","volume":"92","author":"Ahrendt","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0431-3","article-title":"Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy","volume":"9","author":"Ahronian","year":"2017","journal-title":"Genome Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jtho.2017.04.017","article-title":"Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade","volume":"12","author":"Akbay","year":"2017","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","article-title":"Mechanisms of resistance to KRAS(G12C)-targeted therapy.","volume":"11","author":"Akhave","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev.immunol.24.021605.090529","article-title":"Chemokine: Receptor structure, interactions, and antagonism","volume":"25","author":"Allen","year":"2007","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer.","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib10","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1101\/gad.1549407","article-title":"Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis","volume":"21","author":"Ancrile","year":"2007","journal-title":"Genes &\u00a0Development"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10555-006-9004-4","article-title":"The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions","volume":"25","author":"Apte","year":"2006","journal-title":"Cancer and Metastasis Reviews"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib12","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3389\/fonc.2019.01384","article-title":"Lung cancer heterogeneity in modulation of Th17\/IL17A responses","volume":"9","author":"Armstrong","year":"2019","journal-title":"Frontiers in\u00a0Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib13","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib14","doi-asserted-by":"crossref","first-page":"9405","DOI":"10.1096\/fj.201902990R","article-title":"CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"34","author":"Awaji","year":"2020","journal-title":"The FASEB Journal"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fimmu.2014.00276","article-title":"Th17 cells in cancer: The ultimate identity crisis","volume":"5","author":"Bailey","year":"2014","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mdu549","article-title":"Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis","volume":"26","author":"Barrera","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib17","first-page":"2971","article-title":"Autocrine interleukin-1beta production in leukemia: Evidence for the involvement of mutated RAS","volume":"59","author":"Beaupre","year":"1999","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib18","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0959-8049(20)31089-3","article-title":"Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b\/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling","volume":"138","author":"Bendell","year":"2020","journal-title":"European Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib19","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/349117a0","article-title":"The GTPase superfamily: Conserved structure and molecular mechanism","volume":"349","author":"Bourne","year":"1991","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004364","article-title":"SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates","volume":"10","author":"Bowen","year":"2014","journal-title":"PLoS Genetics"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib22","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/0008-5472.CAN-15-2388","article-title":"IL6 trans-signaling promotes KRAS-driven lung carcinogenesis","volume":"76","author":"Brooks","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbcan.2008.05.001","article-title":"Many faces of Ras activation","volume":"1786","author":"Buday","year":"2008","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Reviews on Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib24","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1038\/ncomms9859","article-title":"Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis","volume":"6","author":"Bunda","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib26","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-15-2840","article-title":"IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras-mutant lung cancer","volume":"76","author":"Caetano","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib29","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1034\/j.1600-065X.2003.00028.x","article-title":"GTPases and T cell activation","volume":"192","author":"Cantrell","year":"2003","journal-title":"Immunological Reviews"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib31","first-page":"4785","article-title":"Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene","volume":"54","author":"Castelli","year":"1994","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib32","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.3390\/ijms23169391","article-title":"KRAS-mutant non-small-cell lung cancer: From past efforts to future challenges","volume":"23","author":"Ceddia","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib33","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3390\/jcm11061627","article-title":"Correlation of KRAS G12C mutation and high PD-L1 expression with clinical outcome in NSCLC patients treated with anti-PD1 immunotherapy","volume":"11","author":"Cefal\u00ec","year":"2022","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib34","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1073\/pnas.1319051111","article-title":"T helper 17 cells play a critical pathogenic role in lung cancer","volume":"111","author":"Chang","year":"2014","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2011.03.018","article-title":"Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation","volume":"34","author":"Chaudhry","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib36","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1002\/cam4.4739","article-title":"The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-mutant non-small cell lung cancer","volume":"11","author":"Chen","year":"2022","journal-title":"Cancer Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib37","article-title":"IL-6: The link between inflammation, immunity and breast cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Frontiers in\u00a0Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib38","first-page":"729","article-title":"Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer","volume":"9","author":"Chen","year":"2003","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-021-01127-w","article-title":"Emerging strategies to target RAS signaling in human cancer therapy","volume":"14","author":"Chen","year":"2021","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib40","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","article-title":"KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2019.01.013","article-title":"Kras(G12D) mutation contributes to regulatory T cell conversion through activation of the MEK\/ERK pathway in pancreatic cancer.","volume":"446","author":"Cheng","year":"2019","journal-title":"Cancer Letters"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib43","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1158\/0008-5472.CAN-19-0343","article-title":"IL6 promotes a STAT3-PRL3 feedforward loop via SHP2 repression in multiple myeloma","volume":"79","author":"Chong","year":"2019","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib45","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-11-0908","article-title":"STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis","volume":"71","author":"Corcoran","year":"2011","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib46","first-page":"828","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nature Reviews:\u00a0Drug Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib47","article-title":"Kras and tumor immunity: Friend or foe?","volume":"8","author":"Cullis","year":"2018","journal-title":"Cold Spring Harbor Perspectives\u00a0in\u00a0Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib48","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","article-title":"The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway","volume":"20","author":"Dance","year":"2008","journal-title":"Cellular Signalling"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib49","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.4497","article-title":"SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors","volume":"24","author":"Dardaei","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib50","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","article-title":"Tumor cell-derived il1beta promotes desmoplasia and immune suppression in pancreatic cancer.","volume":"80","author":"Das","year":"2020","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib51","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/1878-0261.13151","article-title":"Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment","volume":"16","author":"Dawson","year":"2022","journal-title":"Molecular Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/138920211794520132","article-title":"Genetic and epigenetic alterations in pancreatic carcinogenesis","volume":"12","author":"Delpu","year":"2011","journal-title":"Current Genomics"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib53","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3389\/fonc.2019.01556","article-title":"Understanding the complexity of the tumor microenvironment in K-ras mutant lung cancer: Finding an alternative path to prevention and treatment","volume":"9","author":"Deng","year":"2019","journal-title":"Frontiers in\u00a0Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib54","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3390\/cancers11122010","article-title":"Targeting the tumor microenvironment: An unexplored strategy for mutant KRAS tumors","volume":"11","author":"Dias Carvalho","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D\u2019Incecco","year":"2015","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib56","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib57","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/cncr.23615","article-title":"Interleukin-6 predicts recurrence and survival among head and neck cancer patients","volume":"113","author":"Duffy","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib58","article-title":"Targets of immune escape mechanisms in cancer: Basis for development and evolution of cancer immune checkpoint inhibitors","volume":"12","author":"Dutta","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0165-2478(93)90156-V","article-title":"The effect of H-ras expression on tumorigenicity and immunogenicity of Balb\/c 3T3 fibroblasts","volume":"39","author":"Ehrlich","year":"1993","journal-title":"Immunology Letters"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1242\/jcs.037226","article-title":"A new mechanism for the regulation of Gab1 recruitment to the plasma membrane","volume":"122","author":"Eulenfeld","year":"2009","journal-title":"Journal of Cell Science"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib61","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/JCO.2020.38.15_suppl.4018","article-title":"CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer","volume":"38","author":"Fakih","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib62","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib63","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2020","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib64","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib65","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1177\/0300060518800588","article-title":"Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer","volume":"46","author":"Feng","year":"2018","journal-title":"The Journal of International Medical Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Seminars in Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib67","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1080\/07357900801918611","article-title":"Gemcitabine combined with Gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II study of the hellenic cooperative oncology group with biomarker evaluation","volume":"26","author":"Fountzilas","year":"2008","journal-title":"Cancer Investigation"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.lungcan.2021.04.002","article-title":"Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19\/16 trial","volume":"156","author":"Froesch","year":"2021","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib69","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccr.2011.03.002","article-title":"Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression","volume":"19","author":"Fukuda","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2021.05.021","article-title":"A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer","volume":"157","author":"Fung","year":"2021","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib71","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: Identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Garcia Fortanet","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib72","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib73","doi-asserted-by":"crossref","first-page":"v163","DOI":"10.1093\/annonc\/mdz244.008","article-title":"446PD\u2014Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours","volume":"30","author":"Govindan","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005061","article-title":"A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis","volume":"4","author":"Granville","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib76","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2174\/156800910793357943","article-title":"The crosstalk of RAS with the TGF-\u03b2 family during carcinoma progression and its implications for targeted cancer therapy","volume":"10","author":"Grusch","year":"2010","journal-title":"Current Cancer Drug Targets"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2017.250","article-title":"SHP2 is required for BCR-ABL1-induced hematologic neoplasia","volume":"32","author":"Gu","year":"2018","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib78","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.cell.2018.11.048","article-title":"NKG2A, a new kid on the immune checkpoint block","volume":"175","author":"Haanen","year":"2018","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib80","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1158\/1535-7163.MCT-19-0170","article-title":"Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-mutant cancers","volume":"18","author":"Hao","year":"2019","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib81","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: An open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib82","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2021.10.003","article-title":"HER2 mediates clinical resistance to the KRAS(G12C) inhibitor sotorasib, which is overcome by co-targeting SHP2.","volume":"159","author":"Ho","year":"2021","journal-title":"European Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1499-3872(14)60259-9","article-title":"Interleukin-6: A villain in the drama of pancreatic cancer development and progression","volume":"13","author":"Holmer","year":"2014","journal-title":"Hepatobiliary & Pancreatic Diseases International"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib84","first-page":"714","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nature Reviews:\u00a0Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib85","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1101\/gad.348787.121","article-title":"USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer","volume":"35","author":"Hou","year":"2021","journal-title":"Genes & Development"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib86","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: From undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib87","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib88","article-title":"Targeting the MAPK pathway in RAS mutant cancers","volume":"8","author":"Hymowitz","year":"2018","journal-title":"Cold Spring Harbor Perspectives\u00a0in\u00a0Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13050653","article-title":"Targeting KRAS in solid tumors: Current challenges and future opportunities of novel KRAS inhibitors","volume":"13","author":"Indini","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib90","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/150960","article-title":"Clinical relevance of KRAS in human cancers","volume":"2010","author":"Jan\u010d\u00edk","year":"2010","journal-title":"Journal of Biomedicine and Biotechnology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib91","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","article-title":"Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study","volume":"14","author":"J\u00e4nne","year":"2013","journal-title":"The Lancet Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib92","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib93","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/sj.onc.1209237","article-title":"K-ras activation generates an inflammatory response in lung tumors","volume":"25","author":"Ji","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib94","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/OTT.S340392","article-title":"Targeting KRAS (G12C)-mutated advanced colorectal cancer: Research and clinical developments","volume":"15","author":"Ji","year":"2022","journal-title":"OncoTargets and Therapy"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib95","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2017.01.002","article-title":"The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting","volume":"111","author":"Jonckheere","year":"2017","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib97","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1038\/s41388-021-01777-7","article-title":"CRISPR screens identify a novel combination treatment targeting BCL-X(L) and WNT signaling for KRAS\/BRAF-mutated colorectal cancers.","volume":"40","author":"Jung","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib98","first-page":"8","article-title":"Phenotypic switching of naive T cells to immune-suppressive treg-like cells by mutant KRAS","author":"Kalvala","year":"2019","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14728222.2022.2066518","article-title":"Targeting SHP2 phosphatase in hematological malignancies","volume":"26","author":"Kanumuri","year":"2022","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","article-title":"Yap1 activation enables bypass of oncogenic kras addiction in pancreatic cancer","volume":"158","author":"Kapoor","year":"2014","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib101","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1128\/MCB.01225-07","article-title":"Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality","volume":"27","author":"Ke","year":"2007","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib102","article-title":"Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC","volume":"8","author":"Keegan","year":"2020","journal-title":"Journal for\u00a0ImmunoTherapy\u00a0of\u00a0Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib103","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00002371-199903000-00007","article-title":"A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors","volume":"22","author":"Khleif","year":"1999","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225599","article-title":"Oncogenic KRAS: Signaling and drug resistance","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib105","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A convergence-based framework for cancer drug resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib106","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/CIRCULATIONAHA.107.728865","article-title":"Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase\/mitogen-activated protein kinase and RhoA signaling pathways","volume":"117","author":"Kontaridis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib107","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature05970","article-title":"IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.","volume":"448","author":"Korn","year":"2007","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib108","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","article-title":"Myc cooperates with Ras by programming inflammation and immune suppression","volume":"171","author":"Kortlever","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib109","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031450","article-title":"PI3K: A crucial piece in the RAS signaling puzzle","volume":"8","author":"Krygowska","year":"2018","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-021-02225-w","article-title":"The path to the clinic: A comprehensive review on direct KRASG12C inhibitors","volume":"41","author":"Kwan","year":"2022","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000842","article-title":"Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition","volume":"8","author":"Laino","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib112","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00384-011-1232-6","article-title":"IL-23\/IL-23R: Potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma","volume":"26","author":"Lan","year":"2011","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"Journal of Immunology Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib114","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib115","first-page":"15","article-title":"Molecular inhibition of RAS signalling to target ageing and age-related health","author":"Laskovs","year":"2022","journal-title":"Disease Models & Mechanisms"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib116","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib117","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12967-015-0555-4","article-title":"The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts","volume":"13","author":"Le Rolle","year":"2015","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib118","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib119","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","article-title":"Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer","volume":"19","author":"Lesina","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib121","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s41416-022-01743-4","article-title":"Biomarkers of response to PD-1 pathway blockade","volume":"126","author":"Li","year":"2022","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib122","article-title":"Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib123","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-\u03b2 regulation of immune responses","volume":"24","author":"Li","year":"2006","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib124","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib125","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cell.2010.02.021","article-title":"Th17 and regulatory T cells in mediating and restraining inflammation","volume":"140","author":"Littman","year":"2010","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib126","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","article-title":"The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity","volume":"470","author":"Liu","year":"2020","journal-title":"Cancer Letters"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib127","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","article-title":"The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity","volume":"470","author":"Liu","year":"2020","journal-title":"Cancer Letters"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib128","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Communications"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib129","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1016\/j.apsb.2021.03.037","article-title":"Strategies to overcome drug resistance using SHP2 inhibitors","volume":"11","author":"Liu","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2016.08.002","article-title":"The CXCL8-CXCR1\/2 pathways in cancer","volume":"31","author":"Liu","year":"2016","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib131","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-018-0223-4","article-title":"Ras enhances TGF-\u03b2 signaling by decreasing cellular protein levels of its type II receptor negative regulator SPSB1","volume":"16","author":"Liu","year":"2018","journal-title":"Cell Communication and Signaling"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib132","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2017.06.003","article-title":"A thirty-year quest for a role of R-Ras in cancer: From an oncogene to a multitasking GTPase","volume":"403","author":"Liu","year":"2017","journal-title":"Cancer Letters"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib133","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-3083.1996.d01-73.x","article-title":"Multiple levels of MHC class I down-regulation by ras oncogenes","volume":"43","author":"Lohmann","year":"1996","journal-title":"Scandinavian Journal of Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib134","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","article-title":"SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo","volume":"24","author":"Mainardi","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib135","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41591-018-0023-9","article-title":"SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo","volume":"24","author":"Mainardi","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: Current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib137","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nature18600","article-title":"A combinatorial strategy for treating KRAS-mutant lung cancer","volume":"534","author":"Manchado","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib138","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000110081","article-title":"Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo","volume":"45","author":"Mannell","year":"2008","journal-title":"Journal of Vascular Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib139","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/j.1460-2075.1995.tb07316.x","article-title":"Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation","volume":"14","author":"Marais","year":"1995","journal-title":"The EMBO Journal"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib140","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay4458","article-title":"Molecular mechanism of SHP2 activation by PD-1 stimulation","volume":"6","author":"Marasco","year":"2020","journal-title":"Science Advances"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib141","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-016-0551-1","article-title":"Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis","volume":"15","author":"Marshall","year":"2016","journal-title":"Molecular Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib142","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1002\/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F","article-title":"The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients","volume":"92","author":"Masuya","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib143","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ccr.2014.03.014","article-title":"Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia","volume":"25","author":"McAllister","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib144","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1093\/nar\/11.23.8221","article-title":"Regional chromosomal localization of N-ras, K-ras-1, K-ras-2 and myb oncogenes in human cells","volume":"11","author":"McBride","year":"1983","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib145","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.celrep.2016.05.085","article-title":"Neutrophil-Derived IL-1\u03b2 Impairs the Efficacy of NF-\u03baB Inhibitors against Lung Cancer","volume":"16","author":"McLoed","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib146","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","article-title":"KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition","volume":"25","author":"Misale","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib147","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/nm1294","article-title":"Induction of interleukin-8 preserves the angiogenic response in HIF-1\u03b1\u2013deficient colon cancer cells","volume":"11","author":"Mizukami","year":"2005","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib148","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gde.2006.12.011","article-title":"The role of Shp2 (PTPN11) in cancer","volume":"17","author":"Mohi","year":"2007","journal-title":"Current Opinion in Genetics & Development"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib149","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1556-0864(15)31506-9","article-title":"The Ras\/Raf\/MAPK Pathway","volume":"1","author":"Molina","year":"2006","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib150","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1126\/science.8503013","article-title":"Complexes of Ras\u22c5GTP with Raf-1 and mitogen-activated protein kinase kinase","volume":"260","author":"Moodie","year":"1993","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib151","first-page":"12","article-title":"Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer","volume":"32","author":"Moo-Young","year":"2009","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib152","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8780","article-title":"Therapeutic KRAS(G12C) inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers","volume":"8","author":"Mugarza","year":"2022","journal-title":"Science Advances"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib153","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41467-017-00942-5","article-title":"Survival of pancreatic cancer cells lacking KRAS function","volume":"8","author":"Muzumdar","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cellular & Molecular Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib155","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-021-01629-x","article-title":"Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models","volume":"126","author":"Nakayama","year":"2022","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib156","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nature Cell Biology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib157","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3389\/fimmu.2019.02468","article-title":"SHP-2 in lymphocytes' cytokine and inhibitory receptor signaling","volume":"10","author":"Niogret","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib158","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer","volume":"33","author":"Niu","year":"2022","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib159","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1172\/JCI23215","article-title":"IL-10\u2013producing and naturally occurring CD4+ Tregs: Limiting collateral damage","volume":"114","author":"O\u2019Garra","year":"2004","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib160","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/carcin\/bgp198","article-title":"ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis","volume":"30","author":"O'Hayer","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib161","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib162","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib163","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/cr.2008.316","article-title":"Roles of TGF\u03b2 in metastasis","volume":"19","author":"Padua","year":"2009","journal-title":"Cell Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib164","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0092-8674(03)01077-8","article-title":"Specificity in signal transduction: From phosphotyrosine-SH2 domain interactions to complex cellular systems","volume":"116","author":"Pawson","year":"2004","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073616","article-title":"Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-RAS mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-\u03b3","volume":"8","author":"Petanidis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib166","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/cancers14041030","article-title":"Morphological and molecular characterization of KRAS G12C-mutated lung adenocarcinomas","volume":"14","author":"Pirlog","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib167","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1535-7163.MCT-15-0253","article-title":"Targeting G-quadruplex DNA structures by EMICORON has a strong antitumor efficacy against advanced models of human colon cancer","volume":"14","author":"Porru","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib168","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.18632\/oncotarget.6906","article-title":"CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer","volume":"7","author":"Purohit","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib169","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: Weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib170","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib171","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2019.00121","article-title":"The Ras superfamily of small GTPases in non-neoplastic cerebral diseases","volume":"12","author":"Qu","year":"2019","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib172","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-14-3042","article-title":"Interleukin-6 prevents the initiation but enhances the progression of lung cancer","volume":"75","author":"Qu","year":"2015","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib173","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1158\/0008-5472.CAN-19-3038","article-title":"Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment","volume":"80","author":"Quintana","year":"2020","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib174","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051321","article-title":"Direct targeting KRAS mutation in non-small cell lung cancer: Focus on resistance","volume":"14","author":"Reita","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib176","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib177","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.immunol.18.1.217","article-title":"The biology of chemokines and their receptors","volume":"18","author":"Rossi","year":"2000","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib178","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","article-title":"Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo","volume":"23","author":"Rota","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib179","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunological Reviews"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib180","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","article-title":"Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase","volume":"24","author":"Ruess","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib181","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","article-title":"Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase","volume":"24","author":"Ruess","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib182","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib183","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition.","volume":"26","author":"Ryan","year":"2020","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib184","article-title":"Landscape of KRAS(G12C), associated genomic alterations, and interrelation with immuno-oncology biomarkers in KRAS-mutated cancers","volume":"6","author":"Salem","year":"2022","journal-title":"JCO\u00a0Precision\u00a0Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib185","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1146\/annurev.immunol.18.1.593","article-title":"The role of chemokine receptors in primary, effector, and memory immune responses","volume":"18","author":"Sallusto","year":"2000","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib186","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1146\/annurev.immunol.18.1.593","article-title":"The role of chemokine receptors in primary, effector, and memory immune responses","volume":"18","author":"Sallusto","year":"2000","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib187","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: Promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib188","doi-asserted-by":"crossref","first-page":"a022236","DOI":"10.1101\/cshperspect.a022236","article-title":"Regulation of the immune response by TGF-\u03b2: From conception to autoimmunity and infection","volume":"9","author":"Sanjabi","year":"2017","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib189","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","article-title":"K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib191","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0092-8674(02)00966-2","article-title":"Ligand-induced, receptor-mediated dimerization and activation of EGF receptor","volume":"110","author":"Schlessinger","year":"2002","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib192","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","article-title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","volume":"31","author":"Schoenfeld","year":"2020","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib193","first-page":"1275","article-title":"Suppression of MHC class I antigens in oncogenic transformants: Association with decreased recognition by cytotoxic T lymphocytes","volume":"24","author":"Seliger","year":"1996","journal-title":"Experimental Hematology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib194","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24557","article-title":"Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells","volume":"125","author":"Sers","year":"2009","journal-title":"International Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib195","doi-asserted-by":"crossref","DOI":"10.3390\/genes12050662","article-title":"The role of wild-type RAS in oncogenic RAS transformation","volume":"12","author":"Sheffels","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib196","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta.","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Letters"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib197","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41587-019-0382-x","article-title":"Grail of RAS cancer drugs within reach","volume":"38","author":"Sheridan","year":"2020","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib198","article-title":"High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer","volume":"12","author":"Silva","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib199","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib200","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","article-title":"A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival","volume":"15","author":"Singh","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib201","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107966","article-title":"Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials","volume":"230","author":"Song","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib203","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib204","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","article-title":"Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis","volume":"6","author":"Sparmann","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib205","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib206","article-title":"PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer","volume":"9","author":"Stein","year":"2021","journal-title":"Journal for\u00a0ImmunoTherapy\u00a0of\u00a0Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib207","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","article-title":"Dragging ras back in the ring","volume":"25","author":"Stephen","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib208","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1172\/JCI65180","article-title":"Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation","volume":"123","author":"Stewart","year":"2013","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib209","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166626","article-title":"RAS-mitogen-activated protein kinase signal is required for enhanced PD-L1 expression in human lung cancers","volume":"11","author":"Sumimoto","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib210","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.3390\/cancers13235956","article-title":"Targeting oncogenic KRAS in non-small-cell lung cancer","volume":"13","author":"Sunaga","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib211","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1158\/0008-5472.CAN-06-3211","article-title":"Transforming growth factor beta signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses","volume":"67","author":"Suzuki","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib212","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-21-0856","article-title":"KRAS inhibitor resistance in MET-amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and Non-RAS-mediated cell signaling mechanisms","volume":"27","author":"Suzuki","year":"2021","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib213","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080885","article-title":"Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer","volume":"8","author":"Tan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib214","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation.","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib215","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harbor Perspectives\u00a0in\u00a0Biology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib216","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2159-8290.CD-21-0369","article-title":"Combined inhibition of SHP2 and CXCR1\/2 promotes antitumor T-cell response in NSCLC","volume":"12","author":"Tang","year":"2022","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib217","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2159-8290.CD-21-0369","article-title":"Combined inhibition of SHP2 and CXCR1\/2 promotes antitumor T-cell response in NSCLC","volume":"12","author":"Tang","year":"2022","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib218","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/bjc.1994.175","article-title":"Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients","volume":"69","author":"Tartour","year":"1994","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib219","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/07357900600814771","article-title":"Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer","volume":"24","author":"Tas","year":"2006","journal-title":"Cancer Investigation"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib220","article-title":"IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients","volume":"9","author":"Tobin","year":"2019","journal-title":"Frontiers in\u00a0Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib221","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-18-0915","article-title":"Shipping out MEK inhibitor resistance with SHP2 inhibitors","volume":"8","author":"Torres-Ayuso","year":"2018","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib222","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib223","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1073\/pnas.1412811112","article-title":"K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif","volume":"112","author":"Tsai","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib224","first-page":"168","article-title":"Bisphosphonates and statins inhibit expression and secretion of MIP-1\u03b1 via suppression of Ras\/MEK\/ERK\/AML-1A and Ras\/PI3K\/Akt\/AML-1A pathways","volume":"5","author":"Tsubaki","year":"2015","journal-title":"American Journal\u00a0of\u00a0Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib225","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/1759-7714.14448","article-title":"Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations","volume":"13","author":"Uehara","year":"2022","journal-title":"Thoracic Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib226","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","article-title":"MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects","volume":"22","author":"Verma","year":"2021","journal-title":"Nature Immunology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib227","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1126\/science.1062023","article-title":"The guanine nucleotide-binding switch in three dimensions","volume":"294","author":"Vetter","year":"2001","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib228","first-page":"842","article-title":"Ras superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy?","volume":"10","author":"Vigil","year":"2010","journal-title":"Nature Reviews:\u00a0Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib229","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s11523-017-0530-5","article-title":"A multi-arm phase I study of the PI3K\/mTOR inhibitors PF-04691502 and fedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in advanced cancer","volume":"12","author":"Wainberg","year":"2017","journal-title":"Targeted Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib230","article-title":"SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms","volume":"11","author":"Wang","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib231","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12964-023-01063-x","article-title":"Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions","volume":"21","author":"Watterson","year":"2023","journal-title":"Cell Communication and Signaling: CCS"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib232","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib233","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s10555-020-09919-1","article-title":"A perspective on the early days of RAS research","volume":"39","author":"Weiss","year":"2020","journal-title":"Cancer Metastasis Reviews"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib234","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003027","article-title":"Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1,\u00a0or TP53\u00a0comutations: Subgroup results from the phase III IMpower150 trial","volume":"10","author":"West","year":"2022","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib235","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41591-018-0022-x","article-title":"Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition","volume":"24","author":"Wong","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib236","doi-asserted-by":"crossref","first-page":"85876","DOI":"10.18632\/oncotarget.13042","article-title":"Correlation between serum IL-1\u03b2 and miR-144-3p as well as their prognostic values in LUAD and LUSC patients","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib237","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1158\/1078-0432.CCR-0953-03","article-title":"Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3\u2019-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells","volume":"10","author":"Xu","year":"2004","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib238","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib239","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020709","article-title":"KRAS mutations in solid tumors: Characteristics, current therapeutic strategy, and potential treatment exploration","volume":"12","author":"Yang","year":"2023","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib240","article-title":"Myeloid-derived suppressor cells: A new and pivotal player in colorectal cancer progression","volume":"10","author":"Yin","year":"2020","journal-title":"Frontiers in\u00a0Oncology"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib241","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib242","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mc.20607","article-title":"KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach","volume":"49","author":"Yoon","year":"2010","journal-title":"Molecular Carcinogenesis"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib243","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1158\/2326-6066.CIR-17-0554","article-title":"IL17A regulates tumor latency and metastasis in lung adeno and squamous SQ.2b and AD.1 cancer","volume":"6","author":"You","year":"2018","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib244","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1164\/ajrccm.162.5.2002108","article-title":"Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer","volume":"162","author":"Yuan","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib245","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157788","article-title":"Targeting IL-1\u03b2 as an immunopreventive and therapeutic modality for K-ras\u2013mutant lung cancer","volume":"7","author":"Yuan","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib246","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1158\/2159-8290.CD-13-0900","article-title":"Development of siRNA payloads to target KRAS-mutant cancer","volume":"4","author":"Yuan","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib247","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2326-6066.CIR-15-0241","article-title":"Mutant KRAS conversion of conventional T cells into regulatory T cells","volume":"4","author":"Zdanov","year":"2016","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib248","article-title":"Focal adhesion kinase (FAK) inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK-YAP signaling","volume":"8","author":"Zhang","year":"2021","journal-title":"Advanced Science"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib249","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","article-title":"Functions of Shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib250","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1158\/0008-5472.CAN-13-1558-T","article-title":"Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib251","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2326-6066.CIR-14-0016-T","article-title":"CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice","volume":"2","author":"Zhang","year":"2014","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib252","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib253","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.1007\/s13277-015-4675-5","article-title":"Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma","volume":"37","author":"Zheng","year":"2016","journal-title":"Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib254","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1358\/dot.2022.58.4.3400573","article-title":"Sotorasib: A treatment for non-small cell lung cancer with the KRAS G12C\u00a0mutation","volume":"58","author":"Zheng","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib255","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/sj.bjc.6602227","article-title":"Interleukin-8\/CXCL8 is a growth factor for human lung cancer cells","volume":"91","author":"Zhu","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib256","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/2159-8290.CD-13-0646","article-title":"Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit","volume":"4","author":"Zhu","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib257","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2015.00116","article-title":"Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer","volume":"6","author":"Zocche","year":"2015","journal-title":"Frontiers in Genetics"},{"key":"10.1016\/bs.ircmb.2024.01.005_bib258","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nri2742","article-title":"T(H)17 cells in tumour immunity and immunotherapy.","volume":"10","author":"Zou","year":"2010","journal-title":"Nature Reviews. Immunology"}],"container-title":["International Review of Cell and Molecular Biology","Targeting Signaling Pathways in Solid Tumors - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644824000157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644824000157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:23:46Z","timestamp":1753701826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644824000157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443235481"],"references-count":258,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2024.01.005","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}